Plasma Tenascin-C: a prognostic biomarker in heart failure with preserved ejection fraction.

Conclusions: In HFpEF, plasma Tenascin-C is higher compared to age and sex-matched controls and a strong predictor of adverse outcomes.Trial registration: ClinicalTrials.gov: NCT03050593. PMID: 32803990 [PubMed - as supplied by publisher]
Source: Biomarkers - Category: Research Tags: Biomarkers Source Type: research